Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 2/20 | 0.81 |
| ▸ | SELPLG | Q14242 | 1/20 | 0.81 |
| ▸ | SLC5A2 | P31639 | 8/20 | 0.49 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8205205 | 0.90 | SELP (0.98) | SELPSELPLGSLC5A2ACHESLC28A3 | |
| SCHEMBL13390119 | 0.90 | SELP (0.81) | SELPSELPLGSLC5A2ACHESLC28A3 | |
| SCHEMBL7619803 | 0.90 | SELP (0.98) | SELPSELPLGSLC5A2ACHESLC28A3 | |
| Bimosiamose SCHEMBL12182030 | 0.90 | SELP (1.00) | SELPSELPLGSLC5A2ACHESLC28A3 | |
| Bimosiamose SCHEMBL29367817 | 0.90 | SELP (1.00) | SELPSELPLGSLC5A2ACHESLC28A3 | |
| Bimosiamose SCHEMBL29372538 | 0.90 | SELP (1.00) | SELPSELPLGSLC5A2ACHESLC28A3 | |
| SCHEMBL7614341 | 0.90 | SELP (1.00) | SELPSELPLGSLC5A2ACHESLC28A3 | |
| Bimosiamose SCHEMBL2529148 | 0.90 | SELP (1.00) | SELPSELPLGSLC5A2ACHESLC28A3 | |
| SCHEMBL7620761 | 0.90 | SELP (1.00) | SELPSELPLGSLC5A2ACHESLC28A3 | |
| Bimosiamose SCHEMBL14015902 | 0.90 | SELP (1.00) | SELPSELPLGSLC5A2ACHESLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020132220-A1 | Use of selectin antagonists in organ preservation solutions | TEXAS BIOTECHNOLOGY CORPORATION | 2002-09-19 | — | — | US | claimed |
| EP-0840606-B1 | DI- AND TRIVALENT SMALL MOLECULE SELECTIN INHIBITORS | TEXAS BIOTECHNOLOGY CORP (US) | 2000-06-07 | — | — | EP | claimed |
| US-5919768-A | COMPOUNDS WHICH INHIBIT BINDING OF SELECTINS TO SIALYL-LEWIS-X AND SIALYL-LEWIS-A CARBOHYDRATES | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-07-06 | — | — | US | claimed |
| US-20020132220-A1 | Use of selectin antagonists in organ preservation solutions | TEXAS BIOTECHNOLOGY CORPORATION | 2002-09-19 | — | — | US | disclosed |
| EP-0840606-B1 | DI- AND TRIVALENT SMALL MOLECULE SELECTIN INHIBITORS | TEXAS BIOTECHNOLOGY CORP (US) | 2000-06-07 | — | — | EP | disclosed |
| US-5919768-A | COMPOUNDS WHICH INHIBIT BINDING OF SELECTINS TO SIALYL-LEWIS-X AND SIALYL-LEWIS-A CARBOHYDRATES | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132220-A1 | Use of selectin antagonists in organ preservation solutions | SELE, SELPLG, SELL | SELP 4/4885SELPLG 2/4885SLC5A2 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.